Acurastem Inc. received a $839,898.40 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop an UNC13A antisense oligonucleotide treatment for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) from June 1, 2023 to May 31, 2025. The grant funding will support Acurastem's efforts to advance a novel gene therapy targeting UNC13A, a gene implicated in ALS and FTD, using antisense oligonucleotide technology. This award furthers Acurastem's ongoing work developing antisense oligonucleotide treatments for neurodegenerative diseases, having previously received over $15 million from federal agencies including the National Institutes of Health to target genes such as SYF2 and PIKFYVE for ALS and FTD indications.
Generated 2/20/24, 6:51 AM